Iqvia Holdings Inc.

Stocks

IQV

US46266C1053

Market Closed - NYSE Other stock markets 21:00:03 14/07/2026 BST			5-day change	1st Jan Change
207.83 ^USD	+0.13%		-0.19%	-7.80%

07-13	Baird Adjusts IQVIA Price Target to $252 From $249, Maintains Outperform Rating	MT
07-13	Mizuho Adjusts Price Target on IQVIA Holdings to $230 From $215, Maintains Outperform Rating	MT

Transcript : IQVIA Holdings Inc. Presents at Jefferies Global Healthcare Conference 2026, Jun-03-2026 09

Published on 06/03/2026 at 03:20 pm BST - Modified on 06/03/2026 at 04:37 pm BST

S&P Capital IQ

Add MarketScreener to your sources

Presenter Speech
David Windley (Analysts)

Great. Thank you. Good morning, everybody. I'm Dave Windley with Jefferies Healthcare Equity Research. Welcome to our 2026 Global Healthcare Conference. We

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Add MarketScreener to your sources

Latest news about Iqvia Holdings Inc.

07-13	Baird Adjusts IQVIA Price Target to $252 From $249, Maintains Outperform Rating	MT
07-13	Mizuho Adjusts Price Target on IQVIA Holdings to $230 From $215, Maintains Outperform Rating	MT
07-07	Evercore ISI Adjusts Price Target on IQVIA Holdings Inc to $225 From $195	MT
07-07	Argus Adjusts Price Target on IQVIA Holdings to $235 From $215	MT
07-06	HSBC Adjusts Price Target on IQVIA Holdings Inc to $240 From $210	MT
07-06	Glenmark Pharmaceuticals Launches Olanzapine for Injection	MT
07-01	Baird Adjusts Price Target on IQVIA Holdings Inc to $249 From $230, Maintains Outperform Rating	MT
06-22	China closing in but US leads in biotech quality, commercial reach, survey finds	RE
06-22	China closing in but US still leads in biotech innovation, survey finds	RE
06-18	Rothschild & Co Redburn Adjusts IQVIA Price Target to $284 From $287, Maintains Buy Rating	MT
06-17	IQVIA Shares Fall After Morgan Stanley Downgrade	MT
06-17	Morgan Stanley Downgrades IQVIA Holdings to Equalweight From Overweight, Adjusts Price Target to $200 From $225	MT
06-17	Medpace: At the Heart of the Small-Cap Biopharma Crisis
06-17	Glenmark Pharmaceuticals Launches Methylene Blue Injection in US	MT
06-08	TD Cowen Adjusts Price Target on IQVIA to $233 From $213, Maintains Buy Rating	MT